Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oncobiologics, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Oncobiologics, Inc. - Product Pipeline Review - 2015', provides an overview of the Oncobiologics, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Oncobiologics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Oncobiologics, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Oncobiologics, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Oncobiologics, Inc.'s pipeline products Reasons to Buy - Evaluate Oncobiologics, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Oncobiologics, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Oncobiologics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Oncobiologics, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Oncobiologics, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Oncobiologics, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Oncobiologics, Inc. Snapshot 5 Oncobiologics, Inc. Overview 5 Key Information 5 Key Facts 5 Oncobiologics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Oncobiologics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Oncobiologics, Inc. - Pipeline Products Glance 11 Oncobiologics, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Oncobiologics, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Oncobiologics, Inc. - Drug Profiles 13 adalimumab biosimilar 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 bevacizumab biosimilar 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 cetuximab biosimilar 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 denosumab biosimilar 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 golimumab biosimilar 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 tocilizumab biosimilar 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 trastuzumab biosimilar 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ustekinumab biosimilar 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Oncobiologics, Inc. - Pipeline Analysis 21 Oncobiologics, Inc. - Pipeline Products by Target 21 Oncobiologics, Inc. - Pipeline Products by Route of Administration 22 Oncobiologics, Inc. - Pipeline Products by Molecule Type 23 Oncobiologics, Inc. - Pipeline Products by Mechanism of Action 24 Oncobiologics, Inc. - Recent Pipeline Updates 25 Oncobiologics, Inc. - Dormant Projects 27 Oncobiologics, Inc. - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 29 Disclaimer 30
List of Tables
Oncobiologics, Inc., Key Information 5 Oncobiologics, Inc., Key Facts 5 Oncobiologics, Inc. - Pipeline by Indication, 2015 7 Oncobiologics, Inc. - Pipeline by Stage of Development, 2015 9 Oncobiologics, Inc. - Monotherapy Products in Pipeline, 2015 10 Oncobiologics, Inc. - Phase I, 2015 11 Oncobiologics, Inc. - Preclinical, 2015 12 Oncobiologics, Inc. - Pipeline by Target, 2015 21 Oncobiologics, Inc. - Pipeline by Route of Administration, 2015 22 Oncobiologics, Inc. - Pipeline by Molecule Type, 2015 23 Oncobiologics, Inc. - Pipeline Products by Mechanism of Action, 2015 24 Oncobiologics, Inc. - Recent Pipeline Updates, 2015 25 Oncobiologics, Inc. - Dormant Developmental Projects,2015 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.